EXFORGE

LOE Approaching

amlodipine besylate and valsartan

NDAORALTABLET
Approved
Jun 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
47

Mechanism of Action

Angiotensin 2 Receptor Antagonists

Pharmacologic Class:

Angiotensin 2 Receptor Blocker

Clinical Trials (5)

NCT01447485Phase 1Completed

Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients

Started Aug 2011
12 enrolled
HypertensionChronic Kidney DiseaseNephrotic Syndrome
NCT01167153Phase 4Completed

Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients

Started May 2010
564 enrolled
Hypertension
NCT00698646Phase 4Completed

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.

Started Apr 2008
384 enrolled
Hypertension
NCT00745953Phase 4Withdrawn

Regression of Fatty Heart by Valsartan Therapy

Started Aug 2007
0
Metabolic SyndromeLipotoxicity
NCT00627991N/AWithdrawn

Blood Pressure Lowering in Acute Stroke Trial (BLAST)

Started Aug 2007
0
Cerebrovascular Accident